Oncopeptides AB (publ)

OM:ONCO Stock Report

Market Cap: SEK 328.4m

Oncopeptides Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Sofia Heigis

Chief executive officer

SEK 3.2m

Total compensation

CEO salary percentage55.3%
CEO tenure1.6yrs
CEO ownershipn/a
Management average tenure2.2yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Jun 18
An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely

Feb 29
Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely

Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?

Nov 14
Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?

We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully

Jul 26
We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Mar 25
Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Nov 23
Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Sofia Heigis's remuneration changed compared to Oncopeptides's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-SEK 285m

Sep 30 2024n/an/a

-SEK 282m

Jun 30 2024n/an/a

-SEK 263m

Mar 31 2024n/an/a

-SEK 246m

Dec 31 2023SEK 3mSEK 2m

-SEK 249m

Compensation vs Market: Sofia's total compensation ($USD314.51K) is about average for companies of similar size in the Swedish market ($USD247.15K).

Compensation vs Earnings: Insufficient data to compare Sofia's compensation with company performance.

CEO

Sofia Heigis (44 yo)

1.6yrs

Tenure

SEK 3,180,000

Compensation

Ms. Sofia Heigis, M.sc, was Chief Commercial Officer and Managing Director of Germany at Oncopeptides AB (publ) since 2022 until 07 August 2023 and also serves as its CEO since 07 August 2023. Ms. Heigis j...

Leadership Team

NamePositionTenureCompensationOwnership
Sofia Heigis
Chief Executive Officer1.6yrsSEK 3.18mno data
Jakob Lindberg
Chief Scientific Officer2.2yrsSEK 4.84mno data
Rolf Larsson
Founderno datano datano data
Rolf Lewensohn
Founderno datano datano data
Joachim Gullbo
Founderno datano datano data
Kristina Luthman
Founderno datano datano data
Hans Ehrsson
Founderno datano datano data
Peter Nygren
Founderno datano datano data
Henrik Bergentoft
Chief Financial Officer1.3yrsno datano data
Eva Nordström
COO & Deputy MD5.2yrsno datano data
David Augustsson
Director of IR & Communications2.2yrsno datano data
Sara Svardgren
Head of Human Resources6.8yrsno datano data

2.2yrs

Average Tenure

50yo

Average Age

Experienced Management: ONCO's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Per Wold-Olsen
Independent Chairman of the Board6.8yrsSEK 1.63m0.23%
SEK 759.4k
Per Anders Samuelsson
Independent Director13.2yrsSEK 355.00kno data
Cecilia Wennborg
Independent Director8.1yrsSEK 682.50k0.026%
SEK 84.1k
Lori Kunkel
Member of Clinical Advisory Boardno datano datano data
Brian Stuglik
Independent Director6.8yrsSEK 755.00kno data
Christian Jacques
Member of Clinical Advisory Boardno datano datano data
Jennifer Jackson
Independent Director6.3yrsSEK 755.00kno data
Axel Glasmacher
Member of Clinical Advisory Boardno datano datano data
Paul Richardson
Member of Clinical Advisory Boardno datano datano data

6.8yrs

Average Tenure

65.5yo

Average Age

Experienced Board: ONCO's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/19 19:33
End of Day Share Price 2025/03/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncopeptides AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Patrik LingDNB Markets
Peter WelfordJefferies LLC